Huguenel E D, Cohn D, Dockum D P, Greve J M, Fournel M A, Hammond L, Irwin R, Mahoney J, McClelland A, Muchmore E, Ohlin A C, Scuderi P
Bayer Research Center West Haven, Connecticut 06516-4175, USA.
Am J Respir Crit Care Med. 1997 Apr;155(4):1206-10. doi: 10.1164/ajrccm.155.4.9105055.
Intercellular adhesion molecule-1 (ICAM-1) is the cell surface receptor for the major class of human rhinoviruses, and tICAM453, a truncated, soluble form of ICAM-1, has been shown previously to be a potent in vitro inhibitor of rhinovirus. In this report, we have investigated the in vivo efficacy of tICAM453 for the prophylaxis of rhinovirus serotype 16 infection in the chimpanzee. Because chimpanzees do not show clinical symptoms of infection after rhinovirus challenge, infection was followed by measuring antirhinovirus serum antibody responses and detection of virus shedding. By both of these measures, intranasal application of tICAM453 was efficacious in preventing rhinovirus infection in chimpanzees subsequently challenged with infectious doses of virus. These results suggest that the use of soluble rhinovirus receptor to inhibit virus binding to host cells should be feasible in humans.
细胞间黏附分子-1(ICAM-1)是主要类型人鼻病毒的细胞表面受体,而tICAM453是ICAM-1的一种截短的可溶性形式,先前已证明它在体外是一种有效的鼻病毒抑制剂。在本报告中,我们研究了tICAM453在黑猩猩中预防16型鼻病毒感染的体内疗效。由于黑猩猩在鼻病毒攻击后不表现出感染的临床症状,因此通过测量抗鼻病毒血清抗体反应和检测病毒脱落来跟踪感染情况。通过这两种测量方法,鼻内应用tICAM453在预防随后用感染剂量病毒攻击的黑猩猩感染鼻病毒方面是有效的。这些结果表明,使用可溶性鼻病毒受体抑制病毒与宿主细胞的结合在人类中应该是可行的。